ArticleInvestigational new drugs2013

Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck.

Jean-Pascal Machiels et al.PubMed ↗Publisher ↗

No numbers read from the abstract.